Tevimbra

BeiGene, Novartis Drug Alliance Ends; It’s Their Second Terminated Deal This Year

BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.